FW: DEA audit letter (government contact form)

From:

"Gustin, Dave" <dave.gustin@mckesson.com>

To:

"Walker, Donald" <donald.walker@mckesson.com>

Date:

Tue, 15 Nov 2011 14:13:00 +0000

Attachments:

Govt contact form DEA letter 11-11-2011.doc (39.94 kB); Government Contact Form DEA audit.PDF (10.75 kB)

- 1. Failure to activate controlled substances cage and vault electronic alarm monitoring when employees were not present in violation of Title 21, Code of Federal Regulations, Sections 1301.71(a)(9), 1301.72(a)(3)(iv) and 1301.72(b)(4)(v), which states that controlled substance storage are shall be equipped with electronic alarms to detect unauthorized entry.
- 2. Failure to report suspicious controlled substance orders in violation of Title 21, Code of Federal Regulations, Section 1301.74(b), which states that the registrant shall inform DEA of suspicious orders.

I cannot say this is a surprise. They came into the audit before ever seeing anything with a strong feeling that we were not in compliance and seemed set out to prove it.

Jeff's statement, "With everything you are doing here if you are not in compliance at WCH then nobody is" speaks to a predisposition I believe. Dave Gustin DRA North Central

937 840 8553

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Meunier, Kevin
Sent: Monday, November 14, 2011 6:15 PM
To: Tate, Kimbir; Trugman, Ina; #PGRDRC
Cc: Mooney, Scott; Essensa, Marc; Gustin, Dave
Subject: DEA audit letter (government contact form)
Kevin Meunier
DC Manaser

DC Manager
W ashington Court House, OH
Office direct phone: 740-636-8127
Office coll-573-382-4686

PLAINTIFFS TRIAL EXHIBIT
P-42814_00001

MCKSTCT00549558

REPORT OF GOVERNMENT CONTACT

	Distribution Center Name and Number:
ГО:	Don Walker, Regional Directors of Regulatory Affairs, E-mail: #PGRDRC Tracy Jonas, Dave Gustin, Bill de Gutierrez-Mahoney & Michael Oriente, Tom McDonald
CC:	Gary Hilliard, Director of Regulatory Affairs (fax # 817-447-2812) DC Specific VPDO and VPGM
	Ina Trugman, Law Department, 34 th Floor, One Post Street, San Francisco, CA 94104
	Litigation Support Group: Kimbir Tate (cc: Norman Lee; Janet Foo; Michael Gormley; Kathy Menchaca)
1.	Time and date of contact by government representatives: 11/11/2011
2.	Name of government representative(s): Robert Corso
3.	Name of government agency, division, and address at which representative(s) work(s): US Department of Justice Drug Enforcement Administration
	Columbus District Office 500 S. Front Street, Suite 612 Columbus ,Ohio 43215
4.	Purpose of contact: Official Follow up letter of DEA investigation conducted April 12, 2011
5.	If tax is involved, state the nature of the tax, e.g., sales or real estate:
6.	Additional comments:
	The attached letter was delivered to WCH McKesson DC 8164 in regards to the DEA investigation conducted in Arpil. The letter states we have 30 days to respond to the letter with a plan of action.
	Date Signed 11/14/2011 Signature Kevin Meunier

ATTACH COPIES OF ANY DOCUMENTS RECEIVED OR GIVEN

04/12/10

CONFIDENTIAL-SUBJECT TO PROTECTIVE ORDER

MCKSTCT00549559

Date Signed	Signature	

ATTACH COPIES OF ANY DOCUMENTS RECEIVED OR GIVEN

04/12/10

CONFIDENTIAL-SUBJECT TO PROTECTIVE ORDER

MCKSTCT00549560



U. S. Department of Justice

Drug Enforcement Administration Columbus District Office 500 S. Front Street, Suite 612 Columbus, Ohio 43215 (614) 255-4200

www.dea.gov

OCT 2 8 2011

Kevin Meunier, Distribution Center Manager McKesson Drug Company 3000 Kenskill Avenue Washington Courthouse, OH 43160

Dear Mr. Meunier:

From March 31 to April 12, 2011, the Drug Enforcement Administration (DEA), Columbus District Office, conducted an investigation of the McKesson Drug Company. On August 30, 2011, there was a management discussion between you and the investigators. As a result of this investigation, the following discrepancies were noted:

- 1. Failure to activate controlled substances cage and vault electronic alarm monitoring when employees were not present in violation of Title 21, Code of Federal Regulations, Sections 1301.71(a)(9), 1301.72(a)(3)(iv), and 1301.72(b)(4)(v), which states that controlled substance storage areas shall be equipped with electronic alarms to detect unauthorized entry.
- 2. Failure to report suspicious controlled substance orders in violation of Title 21, Code of Federal Regulations, Section 1301.74(b), which states that the registrant shall inform DEA of suspicious orders.

This letter is formal notification that failing to maintain adequate physical and electronic security and failing to report suspicious controlled substances orders constitute violations of the Code of Federal Regulations. At this time, you are being afforded the opportunity to comply with the regulations, which were outlined by the investigators with you on August 30, 2011.

Please advise this office, in writing, within 30 days of the action taken or planned to correct these violations. Please contact Diversion Investigator Stephanie Herman at (614) 255-4200 if you have any questions.

Sincerely,

Robert L. Corso

Special Agent in Charge Detroit Field Division